Search Results

L7 Informatics’ position is that generative AI has been deployed in regulated science with only half the architecture it needs, and that the missing half is an active knowledge graph generated at the point of execution.

L7 Informatics CEO, Vasu Rangadass, Ph.D., examines the architectural principle separating pharmaceutical AI experimentation from enterprise-scale deployment.

L7 CEO Vasu Rangadass, Ph.D., argues that regulated process industries have reached the limits of point-solution modernization and must pivot to unified orchestration to unlock the promise of agentic AI.

• Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions • Scientific and medical titan focused on driving innovation for human health • Will assist with listeria oncology pipeline prioritization, combinations with other oncology-focused biotechnologies and tADC candidate selection for further development

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.